WHO Publishes Toolkit of SOPs for Bacteriology, Mycology and Antimicrobial Susceptibility Testing

The World Health Organization (WHO) has published a new Toolkit of Standard Operating Procedures for Bacteriology, Mycology and Antimicrobial Susceptibility Testing, providing clinical laboratories and laboratory networks with practical, standardised procedures for microbiological testing.

Published in 2026, the toolkit contains more than 70 standard operating procedures (SOPs) covering bacteriology, mycology, general laboratory processes and quality management, supported by bench reference guides and flowcharts.

The publication forms part of WHO’s wider Antimicrobial Resistance Diagnostic Initiative, which aims to strengthen diagnostic capacity, laboratory systems and access to quality-assured testing for bacterial and fungal infections and antimicrobial resistance.

More Than 70 Standard Operating Procedures

WHO states that the toolkit covers the full microbiology testing pathway, including:

  • specimen collection and transport;

  • culture;

  • microscopy;

  • phenotypic identification;

  • antimicrobial susceptibility testing;

  • antifungal susceptibility testing;

  • detection of resistance mechanisms;

  • reporting of results;

  • quality management;

  • biosafety.

The SOPs are designed to provide laboratories with practical templates that can be adopted or adapted to local circumstances.

Purpose of the Toolkit

The primary objective is to provide clinical laboratories with standardised, practical and easy-to-follow SOPs for diagnosing bacterial and fungal infections and performing antimicrobial susceptibility testing.

WHO states that the toolkit is intended to support:

  • accurate and reproducible diagnostic results;

  • antimicrobial susceptibility data;

  • patient care;

  • public health surveillance;

  • AMR monitoring;

  • laboratory training;

  • quality improvement;

  • capacity strengthening.

A Globally Applicable Laboratory Resource

The toolkit is intended to complement existing national and institutional laboratory standards rather than replace them.

WHO describes its added value as a globally applicable package covering bacteriology, mycology and antimicrobial susceptibility testing using widely accessible methods.

It may be used by individual laboratories or to support harmonisation across national laboratory networks.

Full Testing Pathway Covered

The scope includes SOPs for:

  • specimen collection, transport and pre-analytical management;

  • specimen processing, culture and interpretation;

  • microscopy and phenotypic identification;

  • bacterial identification and typing;

  • fungal diagnostics;

  • antimicrobial and antifungal susceptibility testing;

  • resistance mechanism detection;

  • isolate preservation;

  • equipment quality control;

  • sterilisation;

  • biosafety and decontamination;

  • reporting and communication.

This makes the toolkit broader than a set of isolated test procedures.

Bench Reference Guides and Flowcharts

WHO has also developed bench reference guides to accompany selected SOPs.

These are concise visual tools intended to support routine work and provide quick-reference information.

However, WHO makes clear that bench reference guides do not replace the full approved SOP and should always be used alongside the current controlled procedure.

SOPs Must Be Verified or Validated Before Use

One of the most important implementation principles is that laboratories should not simply copy the WHO procedures into routine use without assessment.

Each SOP should undergo appropriate:

  • review;

  • pretesting;

  • verification or validation;

  • formal approval;

  • document control.

WHO states that procedures may be adopted as written or adapted where necessary.

Local Adaptation Is Expected

Before implementation, laboratories should assess whether each SOP fits their:

  • services;

  • equipment;

  • test repertoire;

  • workforce;

  • quality management system;

  • regulatory environment.

Modifications may be needed to reflect differences in:

  • local epidemiology;

  • instrumentation;

  • reagents;

  • specimen pathways;

  • resources;

  • reporting requirements;

  • biosafety arrangements;

  • national policies;

  • applicable regulations.

Decision Pathway for SOP Adoption

The decision pathway on page 14 provides a practical framework for deciding whether a laboratory should adopt, adapt, revise or continue using an existing SOP.

Where no approved SOP exists, the WHO procedure should be compared against local regulatory and accreditation requirements, equipment, reagents and staffing.

Where an SOP already exists, laboratories should compare it with the WHO procedure to identify technical or quality gaps.

The pathway then leads to verification or validation, document control, staff training and routine use.

Laboratory Testing Workflow

The testing pathway shown on page 15 maps SOPs across the laboratory workflow, beginning with specimen collection or isolate referral and moving through:

  • transport and acceptance;

  • specimen processing;

  • bacteriology or mycology pathways;

  • organism identification;

  • susceptibility testing;

  • quality control;

  • result reporting.

This workflow helps laboratories identify which SOPs apply at each stage of testing.

Bacteriology Procedures

The toolkit contains an extensive set of bacteriology procedures.

Examples include processing of:

  • blood cultures;

  • cerebrospinal fluid;

  • sterile body fluids;

  • wound swabs;

  • pus aspirates;

  • tissue and biopsies;

  • sputum;

  • lower respiratory tract specimens;

  • throat swabs;

  • eye specimens;

  • ear specimens;

  • urine;

  • catheter tips;

  • genital specimens;

  • stool.

Conventional Identification Methods

WHO also includes SOPs for conventional microbiological tests such as:

  • bacitracin;

  • bile solubility;

  • CAMP;

  • coagulase;

  • citrate;

  • microscopy;

  • indole;

  • Kligler iron agar;

  • potassium hydroxide string;

  • lysine iron agar;

  • motility;

  • optochin;

  • oxidase;

  • PYR;

  • urease;

  • catalase;

  • DNase;

  • ONPG;

  • X and V factors.

This emphasis on conventional methods is particularly relevant for laboratories without access to highly automated platforms.

Identification of Common Bacterial Pathogens

Specific SOPs address identification of clinically relevant groups and organisms, including:

  • Enterobacterales;

  • non-fermenting gram-negative bacilli;

  • Neisseria species;

  • gram-positive cocci;

  • Salmonella;

  • Burkholderia pseudomallei;

  • Haemophilus species.

Antimicrobial Susceptibility Testing

The toolkit includes several procedures for bacterial antimicrobial susceptibility testing.

These include:

  • disc diffusion;

  • gradient diffusion strips;

  • D-zone testing for inducible clindamycin resistance.

WHO states that the toolkit is aligned with internationally recognised approaches, including CLSI and EUCAST.

Antifungal Susceptibility Testing

The publication also includes dedicated procedures for antifungal susceptibility testing.

Examples include:

  • broth microdilution for Candida species;

  • gradient diffusion;

  • disc diffusion testing for yeasts.

This supports laboratories seeking to strengthen fungal diagnostics alongside bacterial AMR testing.

Detection of Priority Resistance Mechanisms

WHO includes SOPs covering several important antimicrobial resistance mechanisms.

These include:

  • extended-spectrum beta-lactamase (ESBL) production;

  • carbapenemase-producing organisms;

  • colistin resistance;

  • AmpC beta-lactamase production.

These procedures are particularly relevant for clinical management and AMR surveillance.

Candida auris Included

The mycology section includes procedures for yeast identification and diagnostics.

One SOP covers presumptive identification of major Candida species using chromogenic agar, including Candida auris.

Other methods include automated systems, biochemical identification, MALDI-TOF MS and molecular identification.

Cryptococcal Antigen Testing

The toolkit also includes a procedure for cryptococcal antigen lateral flow testing using cerebrospinal fluid and serum.

This expands the toolkit beyond traditional culture and identification methods.

Automated Platforms Are Optional

WHO does not make the toolkit dependent on automated laboratory systems.

Where commercial or automated systems are described, they are provided as examples for laboratories that already use them.

Laboratories without access to these systems may rely on conventional methods included elsewhere in the toolkit.

Alignment with ISO 15189

WHO states that the toolkit is aligned with ISO 15189 principles for medical laboratory quality and competence.

SOPs should form part of the laboratory quality management system and provide evidence that testing is:

  • standardised;

  • validated;

  • monitored;

  • performed by competent personnel.

Quality Control and Quality Assurance

Laboratories are expected to establish appropriate internal quality-control processes.

This includes:

  • validated quality-control materials;

  • equipment calibration;

  • maintenance;

  • assay verification;

  • performance monitoring;

  • external quality assessment or proficiency testing;

  • trend analysis;

  • nonconformity management;

  • corrective and preventive action.

Biosafety Is Integrated Across the Toolkit

WHO emphasises that laboratories remain responsible for safety.

SOPs should identify significant hazards and define control measures based on risk assessment.

This may include:

  • containment;

  • microbiological safety cabinets;

  • personal protective equipment;

  • safe microorganism handling;

  • decontamination.

Critical Results and Reporting

The toolkit includes specific procedures for:

  • reporting critical results;

  • reviewing laboratory reports;

  • authorisation and release of results.

WHO stresses that laboratory results should be communicated accurately, securely and in a timely manner.

SOPs should also define processes for delayed, critical, alert or notifiable results requiring urgent communication.

SOPs Must Be Regularly Updated

WHO recommends periodic review of SOPs according to the laboratory’s quality management system.

For example, reviews may take place:

  • annually;

  • every two years;

  • whenever a change may affect testing, safety, quality control, interpretation or reporting.

Updates may be required following changes to:

  • equipment;

  • reagents;

  • methods;

  • standards;

  • policies;

  • guidance;

  • regulations;

  • audit findings;

  • incidents;

  • nonconformities.

Staff Training and Competency Are Required

Before an SOP is released for routine use, staff should be trained.

Laboratories should also assess competency and retain training and competency records within the quality management system.

This helps ensure that written procedures are correctly translated into actual laboratory practice.

National Laboratory Networks Can Adopt the Toolkit

WHO notes that national authorities may also adopt or adapt the toolkit to establish nationally endorsed SOPs.

At network level, responsibilities should be defined for:

  • review;

  • endorsement;

  • adaptation;

  • version control;

  • implementation;

  • monitoring.

This could help harmonise laboratory practices across multiple facilities.

Developed Through International Expert Review

The toolkit was developed with contributions from WHO collaborating centres and international experts.

Each document underwent independent review by three experts, with significant differences escalated to a five-expert panel for discussion and resolution.

Public Consultation in 2026

WHO also conducted an online public hearing between June and July 2026.

The consultation received responses from 72 participants across 27 countries and all six WHO regions.

Respondents submitted 402 substantive comments relating to individual SOPs and bench guides.

Strong Support from Consultation Participants

WHO reports that:

  • 91% of respondents were likely or very likely to implement or adapt the materials;

  • 96% were likely or very likely to recommend them.

Feedback from the consultation was incorporated into the final toolkit.

Implications for Clinical Laboratories

For clinical microbiology laboratories, the toolkit provides a substantial operational resource for:

  • standardising procedures;

  • identifying gaps;

  • benchmarking current practices;

  • strengthening quality systems;

  • supporting accreditation;

  • improving biosafety;

  • training staff;

  • harmonising susceptibility testing.

Laboratories with existing SOPs can use the WHO toolkit as a gap-analysis and benchmarking tool, while laboratories developing new procedures may use the WHO templates as a starting point.

Implications for IVD Manufacturers

The document is also relevant to IVD manufacturers supplying products used in:

  • microbiology;

  • organism identification;

  • culture;

  • AST;

  • antifungal susceptibility testing;

  • resistance detection;

  • automated identification platforms.

Although the toolkit does not endorse individual commercial products, its standardisation of laboratory workflows may influence how diagnostic products are selected, verified, validated and used in clinical laboratories.

Implications for Regulatory and Quality Teams

For regulatory and quality professionals, the toolkit reinforces several recurring themes:

  • locally validated procedures;

  • controlled documentation;

  • staff competency;

  • traceability;

  • quality assurance;

  • biosafety;

  • alignment with applicable regulations;

  • periodic review.

Importantly, WHO states that each SOP should undergo review and verification or validation before routine implementation.

Supporting the Global AMR Response

The publication complements WHO’s broader 2026 work on essential diagnostics for bacterial and fungal infections and AMR.

Together, these initiatives address both:

  • which diagnostic tests should be available;

  • how those tests should be performed consistently and safely.

For laboratories and health systems, this moves the global AMR strategy from high-level diagnostic priorities toward practical implementation.

Anterior
Anterior

NIST Publishes New Cybersecurity Guide for Small Businesses and Solopreneurs

Próximo
Próximo

WHO Publishes Essential Diagnostic Test Package for Bacterial and Fungal Infections and Antimicrobial Resistance